Jefferies London 2026: Nuvation Bio Founder & CEO David Hung shares an update on the launch of IBTROZI (next-gen ROS1 inhibitor and follow-on pipeline projects
He discusses the launch and his thoughts on any future copetitors in the space. Plus an update on the mIDH1 inhibitor safusidenib, and a drug-drug interaction platform that was the basis for founding the company.
Coverage brought to you by










.png)
